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Abstract
Purpose For critically ill patients undergoing continuous
renal replacement therapy (CRRT), daptomycin dosing
recommendations are scarce. We, therefore, retrospectively
assessed routinely measured daptomycin plasma concen-
trations, daptomycin dose administered and microbiologi-
cal data in 11 critically ill patients with Gram-positive
infections that had received daptomycin once daily.
Methods The retrospective analysis included critically ill
patients treated at the intensive care unit (ICU) who had
daptomycin plasma concentrations measured.
Results Daptomycin dose ranged from 3 to 8 mg/kg/
q24 h in patients undergoing CRRT (n = 7) and 6 to
10 mg/kg/q24 h in patients without CRRT (n = 4). Peak
and trough concentrations showed a high intra- and inter-
patient variability in both groups, independent of the dos-
age per kg body weight. No drug accumulation was
detected in CRRT patients with once-daily daptomycin
dosing. Causative pathogens were Enterococcus faecium
(n = 6), coagulase-negative Staphylococcus (n = 2),
Staphylococcus aureus (n = 2) and unknown in one
patient. Microbiological eradication was successful in 8 of
11 patients. Two of three patients with unsuccessful
microbiological eradication and fatal outcome had an
Enterococcus faecium infection.
Conclusion In critically ill patients undergoing CRRT,
daptomycin exposure with once-daily dosing was similar to
ICU patients with normal renal function, but lower com-
pared to healthy volunteers. Our data suggest that dapto-
mycin once-daily dosing is appropriate in patients
undergoing CRRT.
Keywords Antibiotics  Dosing  Gram-positive infection 
Continuous renal replacement therapy  Intensive care
Introduction
Gram-positive bacteria frequently cause severe infections
in patients hospitalised in the intensive care unit (ICU).
Optimal antibiotic dosing ensuring therapeutic concentra-
tions is essential to reduce the risks of therapeutic failure
and the development of antibiotic resistance. Considering
that sepsis has a high mortality in critically ill patients with
acute kidney injury [1], optimising antibiotic dosing is
crucial in this patient population. On the other hand, drug
accumulation and excessive antibiotic concentrations can
result in an increased risk of adverse events. In our ICU,
daptomycin is used in patients with contraindication to
standard antibiotic therapy with glycopeptides due to its
low nephrotoxic potential. Although very rare cases of
acute eosinophilic pneumonia have been reported [2], its
dose-dependent toxicity is limited to creatine kinase ele-
vation with rare cases of rhabdomyolysis [3]. Daptomycin
is a lipopeptide antibiotic active against Gram-positive
organisms, including methicillin-resistant Staphylococcus
aureus (MRSA) or vancomycin-resistant pathogens.
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Daptomycin resistance has only rarely been reported in
Staphylococcus aureus [4, 5] and enterococcal strains [6,
7]. Factors like high bacterial load at the infection site and
suboptimal daptomycin exposure have been associated
with treatment failure and loss of daptomycin susceptibil-
ity; therefore, high-dose daptomycin treatment has been
proposed for complicated Gram-positive and enteroccocal
infections [8, 9].
Daptomycin is approved at a dose of 6 mg/kg once daily
for bacteraemia and at 4 mg/kg once daily for soft tissue
infections in adults with normal or mildly impaired renal
function (creatinine clearance [30 ml/min). Twice-daily
dosing has been reported in children [10]. Sepsis often leads to
acute kidney injury and the need for continuous renal
replacement therapy (CRRT) [11]. As daptomycin is mostly
eliminated by the kidneys, dose adjustments are required in
patients with renal insufficiency. However, official dapto-
mycin dosing recommendations for patients undergoing
CRRT are currently not available [3]. The high plasma protein
binding (90–96 %) of daptomycin suggests that the drug may
not be extensively removed by CRRT. However, in a CRRT
model with bovine plasma enriched with daptomycin using
filtration rates of 35 ml/kg/h or higher, daptomycin CRRT
clearance was comparable or even higher ([10 ml/min) than
the clearance in patients with normal renal function (7–10 ml/
min) [12]. In a recent study by Vilay et al. [13], a single
daptomycin dose of 8 mg/kg in critically ill patients under
CRRT resulted in a similar transmembrane clearance [mean
6.3 ml/min ± 2.9 standard deviation (SD)], indicating a good
elimination by CRRT. The authors suggest a dose of 8 mg/kg
once every 48 h, but we worry that exposure to daptomycin
will be insufficient beyond 24 h with a q48 h dosing regimen
[14]. Khadzhynov et al. determined daptomycin steady-state
pharmacokinetics after the administration of 4 mg/kg q48 h
in eight patients undergoing continuous haemodialysis. They,
likewise, conclude that a once every 48 h dosing might be
inappropriate, because of very low daptomycin exposure
during the second half of the dosing interval [15]. Daptomycin
plasma concentrations in our ICU patients undergoing CRRT
and receiving daptomycin q48 h showed low peak and very
low trough concentrations (data not shown) compared to
values found in healthy volunteers with the equivalent doses
[16]. We, therefore, started to administer daptomycin q24 h
along with regular monitoring of peak and trough plasma
concentrations in clinical routine. In this case series, we
present the daptomycin plasma concentrations of critically ill
patients receiving daptomycin once daily.
Materials and methods
In this chart review, we retrospectively gathered data from
critically ill patients with and without CRRT exposed to a
once-daily daptomycin regimen in which daptomycin peak
(Cmax) and trough (Cmin) concentrations had been deter-
mined. Continuous veno-venous haemodiafiltration (CVV-
HDF) or continuous veno-venous haemodialysis (CVVHD)
is used at our ICU and is performed with multiFiltrate
(Fresenius Medical Care, Homburg, Germany) using the
capillary haemofilter AV 1000S (polysulphon, surface area
1.8 m2) or Prismaflex ST150 (Gambro AB, Lund, Sweden)
using the capillary haemofilter AN69 ST (acrylonitrile-
natrium-methylsulphonate, surface area 1.5 m2). The total
combined filtration/dialysate rates are usually maintained
between 30 and 40 ml/kg/h. Samples were taken at the end
of a 30-min daptomycin infusion for the determination of
Cmax and before the next dose for Cmin. They were imme-
diately transported to the laboratory, centrifuged and ana-
lysed by liquid chromatography/mass spectrometry/mass
spectrometry (LC–MS/MS) using a C18 reversed-phase
analytical column, 0.1 % formic acid and methanol as the
mobile phase, and electrospray ionisation. Heparinised
plasma samples were extracted by protein precipitation
after the addition of the internal standard (CB 183253). The
concentration of daptomycin was calculated by linear
regression analysis of the calibration curve ranging from 0.1
to 150 mg/l. The lower limit of the quantification of the
method was 0.03 mg/l, the precision 3.1 % and the accu-
racy 101 %.
Patient characteristics and microbiological data,
including minimum inhibitory concentrations (MICs), if
available, were collected from the patient charts. Micro-
biological eradication was defined as the absence of the
original pathogen in a culture specimen obtained in the
same anatomical site. Data are represented in a descriptive
way. Plasma concentrations measured in our patients and
previously published mean values from healthy volunteers
at steady state [17, 18] were represented graphically. A
linear regression analysis was performed between the total
daily dose and plasma concentrations measured.
Results
Between May 2008 and December 2010, 11 adult patients
admitted to our ICU receiving once-daily daptomycin
treatment were retrospectively analysed. Seven of them had
oliguric renal failure requiring CRRT (daily urine output
\200 ml) and four had normal or mildly impaired renal
function without undergoing CRRT. The daptomycin dose
ranged from 3 to 8 mg/kg/h in patients undergoing CRRT
and 6 to 10 mg/kg/h in patients without CRRT. The patient
characteristics and microbiological data are presented in
Table 1. Peak and trough daptomycin plasma concentra-
tions are shown in Fig. 1a, b, respectively. Peak and trough
concentrations showed high intra- and inter-patient
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variability in both groups. In CRRT patients, daptomycin
plasma concentrations were in the range of those patients
without CRRT. Interestingly, there was no clear correlation
between dosing per kg body weight and daptomycin
plasma concentration (R2 = 0.06). Errors in the estimation
of body weight and some variability in sampling times for
peak values might explain the inconsistency. Considerable
differences in haemodiafiltration rates (HDFRs) were
found, ranging from 29 to 76 ml/kg/h, corresponding to
2,600–4,400 ml/h, depending on body weight. High-vol-
ume haemodiafiltration of C50 ml/kg/h was used in some
patients with septic shock or severe metabolic disturbances.
Although the HDFR is the main determinant of daptomycinT
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Fig. 1 a Daptomycin Cmax concentrations in intensive care unit
(ICU) patients with once-daily daptomycin dosing. b Daptomycin
Cmin concentrations in ICU patients with once-daily daptomycin
dosing. Filled circles patients undergoing continuous renal replace-
ment therapy (CRRT), open circles no CRRT. a Lines mean
daptomycin plasma concentration and standard deviation (dotted
lines) after 4 mg/kg and 6 mg/kg in healthy volunteers, as published
in Dvorchik et al. [16]. b Lines median daptomycin plasma
concentration and range (dotted lines) after 4 mg/kg and 6 mg/kg in
healthy volunteers, as published in Dvorchik et al. [16]
Daily daptomycin in CRRT 555
123
clearance in CRRT, no correlation was found between
plasma concentrations and the HDFR. Trough concentra-
tions (Fig. 1b) were in the range of values measured in
healthy volunteers [16], independent of daily dose given.
However, when doses of 4 mg/kg were used, Cmax
(Fig. 1a) was in the lower range of values measured in
healthy volunteers at the equivalent dose and were sub-
stantially lower at daptomycin doses [6 mg/kg compared
to equivalent doses in healthy volunteers.
Discussion
In our retrospective analysis of critically ill patients under-
going CRRT and receiving daptomycin once daily, we found
highly variable daptomycin exposure and relatively low
daptomycin peak concentrations, despite high per body
weight dosage in some patients compared to healthy volun-
teers. No evidence of excessively high daptomycin plasma
concentrations was found with once-daily dosing, indicating
that once-daily daptomycin dosing might be more appropri-
ate. Our findings are consistent with those of Vilay et al. [13],
who determined daptomycin pharmacokinetics after a single
dose of daptomycin 8 mg/kg in critically ill patients under-
going CRRT and concluded that 8 mg/kg is necessary to
reach sufficient plasma peak levels. Daptomycin exhibits a
concentration-dependent antibacterial activity. In an animal
model, the area under the curve (AUC)/minimal inhibitory
concentration (MIC) ratio and the Cmax/MIC ratio were the
main determinants of its efficacy [19]. A daptomycin Cmax/
MIC ratio of 100–400 was found to exhibit a log2 killing in
Staphylococcus aureus with a daptomycin MIC of 0.5 mg/l.
Peak concentrations of 50–200 mg/l would be necessary to
reach those ratios. The peak concentrations in our patient
population reached a mean of 46 mg/l, with about two-thirds
of the values being below 50 mg/l at steady state. MIC values
were determined in a patient with coagulase-negative
Staphylococcus (MIC 0.125 mg/ml) and in 3 of 6 patients
with Enterococcus faecium (MIC 1.5–3 mg/ml) infection.
The higher MICs for Enterococcus spp. correspond to epi-
demiological MIC distributions published by the European
Committee on Antimicrobial Susceptibility Testing
(EUCAST) in 2005 [20]. As daptomycin exhibits lower
potency against Enterococcus spp., the drug concentrations
measured in our study could, therefore, theoretically be
insufficient to treat Enterococcus ssp. In in vitro models,
higher doses were required in order to achieve the same effect
(80 % of Emax) against Enterococcus faecium (6.8 mg/kg)
compared to Staphylococcus aureus (3.1 mg/kg) [21]. In an
in vitro model with endocardial vegetations of vancomycin-
resistant Enterococcus exposed to daptomycin at concentra-
tions corresponding to 6, 8, 10 and 12 mg/kg daily in vivo,
bactericidal activity was not sustained at doses of 6 mg/kg
and 8 mg/kg, and the development of reduced susceptibility
was observed at doses 6–10 mg/kg, but not at 12 mg/kg [22].
Clinical experience is limited to retrospective observational
studies though. In one study, daptomycin doses of[6 mg/kg
were associated with higher clinical success in enterococcal
infections [23]. However, prospective data in humans with
enterococcal infections comparing daptomycin plasma con-
centrations and outcome are lacking. Nevertheless, based on
the available data and as daptomycin was generally well
tolerated at doses[8 mg/kg [24, 25], doses higher than 6 mg/
kg daily should be considered in complicated enterococcal
infections As the peak levels were relatively low in critically
ill patients undergoing CRRT with HDFR of 30–40 ml/kg/h,
high-dose regimens must be considered in this patient
population.
In two of the patients with enterococcal infection, micro-
biological eradication failed, and both patients died in the
ICU. Both patients were obese and had received doses
ranging from 400 to 850 mg daily, which corresponded to
3–4 and 5–7 mg/kg, respectively. A third patient with septic
shock and fatal outcome had a coagulase-negative Staphy-
lococcus isolated and was treated with a low total daily
daptomycin dose of 250 mg (4 mg/kg). All other patients had
successful microbiological eradication and all of them sur-
vived until ICU discharge. As daptomycin was never given as
a single antibiotic agent, and because ICU severity scores
were substantially higher in non-survivors than in survivors,
it is not possible to make a definite conclusion on daptomycin
exposure and outcome.
The retrospective character of this work and the small
patient number may certainly limit the conclusions drawn
from the present data; however, the data represent real-life
situations, underlining the difficulty in interpreting rou-
tinely performed therapeutic drug monitoring.
In order to prevent under dosing of daptomycin in crit-
ically ill patients, especially those undergoing CRRT, we
suggest a dose of at least 6 mg/kg body weight every 24 h
and recommend regular monitoring of daptomycin con-
centrations. To further elucidate the optimal daptomycin
dose in critically ill patients undergoing CRRT, a pro-
spective dose-finding study is ongoing at our institution
(http://clinicaltrials.gov/ct2/show/NCT01171547).
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